Teristics of study population at baseline assessment Spironolactone group n Mean age (years) Male (n

Teristics of study population at baseline assessment Spironolactone group n Mean age (years) Male (n [ ]) Race (n [ ]) Caucasian African American Other BMI (kg/m2) BP (mmHg) Systolic Diastolic Duration of diabetes (years) Diabetes medications (n [ ]) Metformin Insulin Sulfonylurea Thiazolidinedione GLP-1 analog Dipeptidyl peptidase-4 inhibitor Antihypertensive drugs (n [ ]) Enalapril Amlodipine Statin use (n [ ]) Fasting laboratory data Blood glucose (mg/dL) Total cholesterol (mg/dL) LDL cholesterol (mg/dL) HDL cholesterol (mg/dL) Triglycerides (mg/dL) HbA1c ( ) Serum sodium (mmol/L) Serum potassium (mmol/L) Creatinine clearance price (mL/min) Plasma renin activity (ng/mL/h) Serum angiotensin II (pg/mL) Serum aldosterone (ng/dL) Echocardiography Mitral inflow E (m/s) A (m/s) Deceleration time (ms) E/A ratio Tissue Doppler imaging e’ (m/s) E/e’ ratio Cardiac MRI LV mass index (g/m2) LV ejection fraction ( ) Myocardial extracellular volume 24-h Urine benefits Sodium (mmol/24 h) Creatinine (mg/24 h) Potassium (mmol/24 h) Aldosterone (mg/24 h) 23 56 6 six 17 (74) 17 (74) four (17) 2 (9) 31.4 six 4.5 123 six 11 75 6 7 967 16 (70) 3 (13) 7 (30) 1 (four) 1 (4) 1 (four) 23 (100) 7 (30) 17 (74) 105 6 23 150 six 35 81 6 27 47 six 12 113 six 39 six.six 6 0.four 139.5 6 two.1 4.two six 0.3 129 six 30 1.5 six two.2 18.01 6 eight.89 3.13 6 1.46 HCTZ group 24 53 6 7 13 (54) 17 (71) 6 (25) 1 (four) 32.five six five.4 124 6 14 74 six 9 766 20 (83) three (13) 7 (29) 1 (4) 1 (four) 0 (0) 24 (one hundred) six (25) 20 (83) 106 six 25 153 six 24 82 six 20 45 6 12 130 six 77 7.0 6 0.9 139.0 6 two.1 four.3 six 0.three 126 6 26 2.three 6 three.three 22.59 6 6.17 3.21 six 1.19 Placebo group 17 55 6 ten 10 (59) eight (47) 7 (41) 2 (12) 31.three six four.2 125 six 13 77 6 10 766 16 (94) 3 (18) 7 (41) 0 (0) 2 (12) 0 (0) 17 (100) 4 (24) 11 (65) 105 six 24 139 6 24 75 6 21 41 6 12 120 6 72 7.0 six 0.7 139.two 6 1.5 4.2 six 0.two 124 6 38 2.4 6 three.9 19.15 6 five.82 three.84 6 2.0.76 six 0.14 0.68 six 0.17 220.38 6 37.94 1.15 six 0.23 0.11 6 0.02 7.24 six 2.00 46.four six 12.2 61.4 six 4.5 0.36 six 0.06 291 6 74 1,599.7 6 407.5 97.8 six 15.0 six.49 6 six.0.74 six 0.14 0.66 6 0.16 212.04 six 37.36 1.13 6 0.29 0.11 six 0.03 6.92 6 1.59 43.6 6 ten.9 60.2 6 7.0 0.34 six 0.04 258 6 72 1,510.four six 326.9 91.1 six 19.1 7.19 six 5.0.68 6 0.13 0.67 six 0.17 216.88 six 31.75 1.05 six 0.23 0.11 6 0.02 six.58 6 1.68 46.7 six 11.2 60.4 six 5.0 0.38 six 0.04 256 6 77 1,537.8 6 466.1 88.8 6 29.1 6.17 six 4.APC web information are expressed as mean six SD unless stated otherwise. There were no substantial MyD88 medchemexpress differences in between remedy groups prerandomization.diabetes.diabetesjournals.orgGarg and Associatesa 4-week plasma potassium .5.five mmol/L; no additional hyperkalemia was noted and study staff remained blinded as to treatment. A single participant within the HCTZ group had enalapril elevated to 40 mg everyday for the final four months by his cardiologist. Average therapy duration was 5.9 six 0.5 months for spironolactone, five.6 6 0.9 months for HCTZ, and five.7 6 0.3 months for placebo (P = NS). Table 2 shows the adjustments in study parameters among visits. There had been significant and equivalent decreases in systolic BP with spironolactone and HCTZ. Serum potassium improved drastically with spironolactone but not with other remedies. There have been no important alterations from baseline in HbA1c, total cholesterol, HDL, calculated LDL (cLDL), triglycerides, and BMI with any treatment. Diastolic function, LV mass index, LV ejection fraction, and myocardial extracellular volume were unaffected by therapy.MBF and Flow ReserveComplete MBF and CFR information (Table three) were accessible in 60 participants; four participants had.